

**California Institute of Technology
Administrative Committee on Biosafety
Minutes of the Institutional Biosafety Committee (IBC)**

Date: April 15, 2026 **Time:** 11:00 AM **Location:** Zoom Videoconference

Voting Members: A. Hoelz (Acting Chair), M. Doshi, R. Ismagilov, W. Gao, L. Quenee, N. Siladke, M. Barsever, N. Singh, K. Lencioni, C. Cortese, E. Hisserich
 Nonvoting: 3 attendees
 Other: 1 attendee

Called to order at 11:46 am, with a quorum in attendance.

1. Announcements
There were no announcements.
2. Old Business
There was no old business to report.
3. New Business
 - A. Protocols – Full Committee Review

| | | | | |
|---|--|--------------------|------------------|-----------|
| Protocol: | 25-192 | Review | Expiration Date: | 3/12/2028 |
| Title: | Immunocontraception in the mouse and rat | | | |
| PI Name: | Hay | | | |
| Brief Description of Project: Development and testing of a contraceptive for mice that can be taken as a single injection. This contraceptive consists of an adeno-associated virus (AAV) vector, or plasmid, designed to express antibodies that prevent fertilization through either inhibition of a murine hormone required for reproduction in males and females or blockade of the sperm's ability to bind to components of the murine egg surface membrane. | | | | |
| Biological Materials Review Summary: Biological materials include replication-incompetent viral vectors (AAV), human cell lines, lab strains of E. coli, and animals. | | | | |
| NIH Guidelines: | III-D | Highest BSL Level: | BSL2 | |
| Training: This protocol requires the following biosafety training: Comprehensive Biosafety (BSL2), annual Bloodborne Pathogens and Viral Vector Training. Personnel who have not completed the required training will not begin this work until all appropriate training has been completed and documented. | | | | |
| Review Summary: All facilities, procedures, and practices have been reviewed by the IBC and are considered appropriate and acceptable. | | | | |
| IBC Action/Decision: Approved with Stipulations | | | | |
| ❖ The committee reviewed and unanimously approved lifting the current hold on in vivo work on the protocol subject to the adherence to the following special stipulations, along with all standard stipulations: | | | | |

- AAV transgenes: Synthetic proteins designed to target contraceptive proteins are restricted to targeting of murine proteins only. No work can be done on human targets.
- In vivo experiments are restricted to mice and rats only.
- Publications and proposals will be pre-reviewed by the Office of Research Compliance and the Office of Communications and External Relations.
- Any change in the project or targets requires an IBC amendment and approval prior to project start.
- Prior to sending the biological materials, the external collaborator must provide the lab with computational/modeling data demonstrating the synthetic proteins are specific for murine Juno relative to human Juno. This data must be provided to the IBC for review and approval before receipt of the biological materials by Caltech.

4. Other Business

There was no other business to report.

Next Meeting – May 5, 2026

Meeting adjourned at 12:11 pm

Approved by the IBC 5/5/26